Cleveland Biolabs Inc. (CBLI) and Incuron Announce US and European Patent Allowances for Curaxins
5/14/2013 9:17:28 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BUFFALO, N.Y., May 14, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) and Incuron, LLC, a joint venture between the Company and Bioprocess Capital Ventures, today announced the receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for the Curaxin U.S. Patent Application Number 12/993,018, titled "Inducing Cell Death by Inhibiting Adaptive Heat Shock Response." This patent was recently issued in the Russian Federation, as well. Curaxins include CBL0137, which is a carbazole and CBL0102, which is a quinacrine.
Help employers find you! Check out all the jobs and post your resume.
comments powered by